Roger E. Susi, who serves as CEO, President and Chairman of IRADIMED CORP (NASDAQ:IRMD), sold a total of 7,500 shares of the companys common stock over two days in mid-March 2026, producing proceeds of approximately $762,970.
The disposals took place from March 16 through March 17, 2026, with executed prices spanning $101.18 to $102.43 per share. The stock has been trading close to a 52-week high of $107.90, after delivering a 100% return over the past 12 months.
Breakdown of transactions
On March 16, Susi sold 3,009 shares at a weighted average price of $101.18, for total proceeds of $304,451. The execution prices for that tranche ranged between $100.37 and $101.37. Also on March 16, he sold an additional 1,991 shares at a weighted average of $101.68, totaling $202,400, with execution prices between $101.38 and $101.86. On March 17, Susi sold 2,500 shares at a weighted average price of $102.43, amounting to $256,075; those trades were executed between $102.06 and $102.90.
All of the sales were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Susi adopted on November 5, 2025.
Post-transaction holdings
Following the March transactions, Susis indirect holdings in the company remain substantial. He indirectly holds 2,240,000 shares through the Phillip Susi 2008 Dynasty Trust. Separate holdings include 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust.
Valuation context
At the time of the sales, IRADIMED carried a market capitalization of $1.3 billion and a price-to-earnings ratio of 58.13. InvestingPros analysis, cited in available reports, indicates the stock appears overvalued relative to its Fair Value and places the company on a list of the most overvalued names.
Recent financial performance and analyst attention
IRadimed reported fourth-quarter 2025 results that exceeded analyst expectations on both earnings per share (EPS) and revenue. The companys Q4 2025 outcome topped forecasts, a development that market participants commonly view as relevant to assessments of corporate health and outlook. In the wake of the results, analysts across several firms have continued to follow the company and have issued updates.
The positive Q4 report, combined with active analyst coverage and the insider sale, are among the data points investors and observers are monitoring as they assess IRadimeds near-term performance and valuation.
What investors can access
For investors seeking more detailed analysis of IRADIMEDs valuation and financial condition, a comprehensive Pro Research Report is available for this company and for more than 1,400 other U.S. equities through InvestingPro.
Market participants will likely continue to track the companys earnings trajectory, analyst commentary and insider activity in upcoming quarters.